JP2016528301A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016528301A5 JP2016528301A5 JP2016536497A JP2016536497A JP2016528301A5 JP 2016528301 A5 JP2016528301 A5 JP 2016528301A5 JP 2016536497 A JP2016536497 A JP 2016536497A JP 2016536497 A JP2016536497 A JP 2016536497A JP 2016528301 A5 JP2016528301 A5 JP 2016528301A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- alkyl
- compound
- cough
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 26
- 206010011224 Cough Diseases 0.000 claims 24
- 150000001875 compounds Chemical class 0.000 claims 19
- -1 amino, aminosulfonyl Chemical group 0.000 claims 18
- 208000013116 chronic cough Diseases 0.000 claims 14
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 11
- 125000004181 carboxyalkyl group Chemical group 0.000 claims 11
- 125000001188 haloalkyl group Chemical group 0.000 claims 11
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 10
- 125000000217 alkyl group Chemical group 0.000 claims 10
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 10
- 229910052739 hydrogen Inorganic materials 0.000 claims 10
- 239000001257 hydrogen Substances 0.000 claims 10
- 125000003342 alkenyl group Chemical group 0.000 claims 9
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 9
- 125000003545 alkoxy group Chemical group 0.000 claims 9
- 125000000304 alkynyl group Chemical group 0.000 claims 9
- 150000001408 amides Chemical class 0.000 claims 9
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims 9
- 125000004093 cyano group Chemical group *C#N 0.000 claims 9
- 125000004438 haloalkoxy group Chemical group 0.000 claims 9
- 125000001475 halogen functional group Chemical group 0.000 claims 9
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 9
- 125000005113 hydroxyalkoxy group Chemical group 0.000 claims 9
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 9
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 8
- 206010020751 Hypersensitivity Diseases 0.000 claims 3
- 230000001154 acute effect Effects 0.000 claims 3
- 208000026935 allergic disease Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 230000009610 hypersensitivity Effects 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 230000001537 neural effect Effects 0.000 claims 3
- 208000023504 respiratory system disease Diseases 0.000 claims 3
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361869174P | 2013-08-23 | 2013-08-23 | |
| US61/869,174 | 2013-08-23 | ||
| PCT/US2014/052389 WO2015027212A1 (en) | 2013-08-23 | 2014-08-22 | Diaminopyrimidine p2x3 and p2x 2/3 receptor modulators for treatment of acute, sub-acute or chronic cough |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019055849A Division JP7210348B2 (ja) | 2013-08-23 | 2019-03-25 | 急性、亜急性または慢性の咳を治療するためのジアミノピリミジンｐ２ｘ３およびｐ２ｘ２／３受容体モジュレーター |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016528301A JP2016528301A (ja) | 2016-09-15 |
| JP2016528301A5 true JP2016528301A5 (enExample) | 2017-09-28 |
| JP6546592B2 JP6546592B2 (ja) | 2019-07-17 |
Family
ID=52480919
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016536497A Active JP6546592B2 (ja) | 2013-08-23 | 2014-08-22 | 急性、亜急性または慢性の咳を治療するためのジアミノピリミジンｐ２ｘ３およびｐ２ｘ２／３受容体モジュレーター |
| JP2019055849A Active JP7210348B2 (ja) | 2013-08-23 | 2019-03-25 | 急性、亜急性または慢性の咳を治療するためのジアミノピリミジンｐ２ｘ３およびｐ２ｘ２／３受容体モジュレーター |
| JP2022166618A Active JP7423725B2 (ja) | 2013-08-23 | 2022-10-18 | 急性、亜急性または慢性の咳を治療するためのジアミノピリミジンｐ２ｘ３およびｐ２ｘ２／３受容体モジュレーター |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019055849A Active JP7210348B2 (ja) | 2013-08-23 | 2019-03-25 | 急性、亜急性または慢性の咳を治療するためのジアミノピリミジンｐ２ｘ３およびｐ２ｘ２／３受容体モジュレーター |
| JP2022166618A Active JP7423725B2 (ja) | 2013-08-23 | 2022-10-18 | 急性、亜急性または慢性の咳を治療するためのジアミノピリミジンｐ２ｘ３およびｐ２ｘ２／３受容体モジュレーター |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US9284279B2 (enExample) |
| EP (2) | EP3865134A1 (enExample) |
| JP (3) | JP6546592B2 (enExample) |
| KR (1) | KR102196885B1 (enExample) |
| CN (1) | CN105682659B (enExample) |
| AU (1) | AU2014308606B2 (enExample) |
| CA (1) | CA2921395C (enExample) |
| CL (3) | CL2016000400A1 (enExample) |
| CR (1) | CR20160093A (enExample) |
| IL (1) | IL244131B (enExample) |
| MX (1) | MX367657B (enExample) |
| MY (1) | MY195728A (enExample) |
| NI (1) | NI201600029A (enExample) |
| NZ (1) | NZ716977A (enExample) |
| PE (1) | PE20160431A1 (enExample) |
| PH (1) | PH12016500357A1 (enExample) |
| RU (1) | RU2650118C2 (enExample) |
| SG (1) | SG11201601145RA (enExample) |
| UA (1) | UA118851C2 (enExample) |
| WO (1) | WO2015027212A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2921395C (en) * | 2013-08-23 | 2022-04-26 | Afferent Pharmaceuticals Inc. | Diaminopyrimidine p2x3 and p2x 2/3 receptor modulators for treatment of acute, sub-acute or chronic cough |
| AU2015213681B2 (en) | 2014-02-10 | 2020-03-12 | Respivant Sciences Gmbh | Mast cell stabilizers for lung disease treatment |
| WO2015120389A1 (en) | 2014-02-10 | 2015-08-13 | Patara Pharma, LLC | Mast cell stabilizers treatment for systemic disorders |
| WO2017011729A1 (en) | 2015-07-16 | 2017-01-19 | Patara Pharma, LLC | Combination therapies for the treatment of lung diseases |
| EP3331522A1 (en) | 2015-08-07 | 2018-06-13 | Patara Pharma LLC | Methods for the treatment of mast cell related disorders with mast cell stabilizers |
| WO2017027402A1 (en) | 2015-08-07 | 2017-02-16 | Patara Pharma, LLC | Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders |
| EP4215182A1 (en) * | 2015-09-29 | 2023-07-26 | Afferent Pharmaceuticals Inc. | Diaminopyrimidine p2x3 and p2x2/3 receptor modulators for use in the treatment of cough |
| US9907795B2 (en) * | 2016-01-08 | 2018-03-06 | Nerre Therapeutics Limited | Method of treatment of chronic cough administering orvepitant in combination with other therapeutic agents |
| US10662162B2 (en) * | 2016-03-25 | 2020-05-26 | Afferent Pharmaceuticals, Inc. | Pyrimidines and variants thereof, and uses therefor |
| CA3035528A1 (en) | 2016-08-31 | 2018-03-08 | Respivant Sciences Gmbh | Cromolyn compositions for treatment of chronic cough due to idiopathic pulmonary fibrosis |
| CA3037746A1 (en) | 2016-10-07 | 2018-04-12 | Respivant Sciences Gmbh | Cromolyn compositions for treatment of pulmonary fibrosis |
| EP3554504B1 (en) * | 2016-12-15 | 2022-10-26 | Afferent Pharmaceuticals Inc. | Substituted pyrazole-pyrimidines, variants thereof, and uses thereof |
| US10676444B2 (en) * | 2016-12-20 | 2020-06-09 | Afferent Pharmaceuticals, Inc. | Crystalline salts and polymorphs of a P2X3 antagonist |
| US10111883B1 (en) * | 2017-09-18 | 2018-10-30 | Bellus Health Cough Inc. | Selective P2X3 modulators |
| CN108904507A (zh) * | 2018-02-11 | 2018-11-30 | 赖英杰 | P2x3受体调节剂苯并咪唑化合物在制备抗呼吸疾病药物中的应用 |
| CN112004551A (zh) | 2018-03-15 | 2020-11-27 | 丹米尔治疗有限责任公司 | 3”,5”-二烷氧基苯甲酰基-3’-氨基-3’-脱氧腺苷-5’-三磷酸及其药物用途 |
| JP7502997B6 (ja) * | 2018-04-23 | 2024-07-12 | メルク・シャープ・アンド・ドーム・エルエルシー | フェノキシジアミノピリミジン化合物の新規な合成方法 |
| BR112020022340A2 (pt) | 2018-05-15 | 2021-02-02 | Bayer Aktiengesellschaft | benzamidas substituídas por 1,3-tiazol-2-il para o tratamento de doenças associadas com sensibilização de fibras nervosas |
| JOP20200286A1 (ar) * | 2018-05-15 | 2020-11-09 | Bayer Ag | بنزاميدات مستبدلة بـ 1 ، 3-ثيازول-2-يل للمعالجة من أمراض مصاحبة لتحسس الألياف العصبية |
| EP3826635A4 (en) | 2018-07-23 | 2022-04-27 | Trevi Therapeutics, Inc. | TREATMENT OF CHRONIC COUGH, SHORTNESS OF BREATH AND DYSPNEA |
| CN113559104A (zh) * | 2018-10-05 | 2021-10-29 | 盐野义制药株式会社 | 慢性咳嗽治疗用药物 |
| CN113727716A (zh) | 2019-02-25 | 2021-11-30 | 贝卢斯医疗咳嗽病公司 | 采用p2x3调节剂的治疗 |
| AU2020266699B2 (en) | 2019-04-30 | 2025-12-18 | Beijing Tide Pharmaceutical Co., Ltd. | Salt of diaminopyrimidine compounds, and solid form thereof, preparation method therefor and use thereof |
| MX2021013338A (es) * | 2019-04-30 | 2022-01-24 | Beijing Tide Pharmaceutical Co Ltd | Método para tratar la tos usando un compuesto de diaminopirimidina. |
| AU2020348089B2 (en) | 2019-09-19 | 2025-12-18 | Shionogi & Co., Ltd. | Crystal of 1,3,5-triazine derivative or solvate thereof and method for producing same |
| EP4087569A4 (en) | 2020-01-10 | 2024-01-24 | Trevi Therapeutics, Inc. | METHODS OF ADMINISTRATION OF NALBUPHINE |
| CN111635368B (zh) * | 2020-06-12 | 2021-06-29 | 东莞市东阳光仿制药研发有限公司 | 一种胺化合物的制备方法 |
| CN120019423A (zh) | 2022-10-12 | 2025-05-16 | 软银集团股份有限公司 | 信息处理系统、信息处理装置、控制装置及程序 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI1725540T1 (sl) | 2004-03-05 | 2012-12-31 | F. Hoffmann-La Roche Ag | Diaminopirimidini kot antagonisti P2X3 in P2X2/3 |
| CA2573565A1 (en) * | 2004-07-22 | 2006-02-02 | Duska Scientific Co. | Method of diagnosing, monitoring and treating pulmonary diseases |
| WO2007025901A1 (en) | 2005-09-01 | 2007-03-08 | F. Hoffmann-La Roche Ag | Diaminopyrimidines as p2x3 and p2x2/3 modulators |
| JP4850914B2 (ja) | 2005-09-01 | 2012-01-11 | エフ．ホフマン−ラ ロシュ アーゲー | Ｐ２ｘ３およびｐ２ｘ２／３モジュレーターとしてのジアミノピリミジン |
| JP4820873B2 (ja) * | 2005-09-01 | 2011-11-24 | エフ．ホフマン−ラ ロシュ アーゲー | アリールオキシジアミノピリミジンの合成方法 |
| EP1924564B1 (en) * | 2005-09-01 | 2016-11-09 | F.Hoffmann-La Roche Ag | Diaminopyrimidines as p2x3 and p2x2/3 modulators |
| MX2009003257A (es) * | 2006-10-04 | 2009-04-07 | Hoffmann La Roche | Procedimiento para la sintesis de derivados de fenoxi diaminopirimidina. |
| WO2008104474A1 (en) * | 2007-02-28 | 2008-09-04 | F. Hoffmann-La Roche Ag | Diaminopyrimidines |
| US9550763B2 (en) * | 2012-02-09 | 2017-01-24 | Shionogi & Co., Ltd. | Heterocyclic ring and carbocyclic derivative |
| CA2921395C (en) | 2013-08-23 | 2022-04-26 | Afferent Pharmaceuticals Inc. | Diaminopyrimidine p2x3 and p2x 2/3 receptor modulators for treatment of acute, sub-acute or chronic cough |
| US9222282B2 (en) * | 2013-10-11 | 2015-12-29 | Nexkey, Inc. | Energy efficient multi-stable lock cylinder |
-
2014
- 2014-08-22 CA CA2921395A patent/CA2921395C/en active Active
- 2014-08-22 WO PCT/US2014/052389 patent/WO2015027212A1/en not_active Ceased
- 2014-08-22 US US14/466,713 patent/US9284279B2/en active Active
- 2014-08-22 AU AU2014308606A patent/AU2014308606B2/en active Active
- 2014-08-22 MY MYPI2016000327A patent/MY195728A/en unknown
- 2014-08-22 UA UAA201601740A patent/UA118851C2/uk unknown
- 2014-08-22 SG SG11201601145RA patent/SG11201601145RA/en unknown
- 2014-08-22 KR KR1020167007167A patent/KR102196885B1/ko active Active
- 2014-08-22 CR CR20160093A patent/CR20160093A/es unknown
- 2014-08-22 MX MX2016002289A patent/MX367657B/es active IP Right Grant
- 2014-08-22 CN CN201480058491.3A patent/CN105682659B/zh active Active
- 2014-08-22 JP JP2016536497A patent/JP6546592B2/ja active Active
- 2014-08-22 EP EP21159088.0A patent/EP3865134A1/en active Pending
- 2014-08-22 RU RU2016105581A patent/RU2650118C2/ru active
- 2014-08-22 EP EP14838254.2A patent/EP3035932A4/en not_active Withdrawn
- 2014-08-22 PE PE2016000285A patent/PE20160431A1/es unknown
- 2014-08-22 NZ NZ716977A patent/NZ716977A/en unknown
-
2016
- 2016-02-02 US US15/013,798 patent/US9724346B2/en active Active
- 2016-02-15 IL IL244131A patent/IL244131B/en active IP Right Grant
- 2016-02-22 NI NI201600029A patent/NI201600029A/es unknown
- 2016-02-22 CL CL2016000400A patent/CL2016000400A1/es unknown
- 2016-02-23 PH PH12016500357A patent/PH12016500357A1/en unknown
-
2017
- 2017-08-01 US US15/665,595 patent/US10206922B2/en active Active
-
2018
- 2018-08-08 CL CL2018002138A patent/CL2018002138A1/es unknown
- 2018-08-08 CL CL2018002137A patent/CL2018002137A1/es unknown
-
2019
- 2019-03-25 JP JP2019055849A patent/JP7210348B2/ja active Active
-
2022
- 2022-10-18 JP JP2022166618A patent/JP7423725B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016528301A5 (enExample) | ||
| RU2016105581A (ru) | Способ лечения острого, хронического и подострого кашля и непреодолимого желания откашляться | |
| PH12015502691A1 (en) | Use of high dose pridopidine for treating huntington's disease | |
| JP2015532296A5 (enExample) | ||
| JP2016505637A5 (enExample) | ||
| CY1119490T1 (el) | Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων | |
| EP4227304A3 (en) | Thiadiazole analogs and their use for treating diseases associated with a deficiency of smn motor neurons | |
| RU2013150861A (ru) | Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний | |
| JP2016508134A5 (enExample) | ||
| JP2013519675A5 (enExample) | ||
| JP2015501783A5 (enExample) | ||
| JP2016510326A5 (enExample) | ||
| JP2017514910A5 (enExample) | ||
| JP2016534063A5 (enExample) | ||
| HRP20171648T1 (hr) | Supstituirani piperidil-etil-pirimidin kao inhibitor grelin-o-acil-transferaze | |
| EA201891931A1 (ru) | Новые ингибиторы фосфатидилинозитол-3-киназы гамма | |
| RU2018113718A (ru) | Новые соединения | |
| EA201691058A1 (ru) | Производные пирролопирролона и их применение для лечения заболеваний | |
| JP2015510916A5 (enExample) | ||
| JP2016537338A5 (enExample) | ||
| RU2014141893A (ru) | Применение производной пиразола в лечении острых приступов хронической обструктивной болезни легких | |
| MX381440B (es) | Composicion farmaceutica para tratar colitis ulcerativa. | |
| EA201990664A1 (ru) | Производные 5-[2-(пиридин-2-иламино)-1,3-тиазол-5-ил]-2,3-дигидро-1h-изоиндол-1-она и их применение в качестве двойных ингибиторов фосфатидилинозитол-3-киназ дельта и гамма | |
| JP2015516419A5 (enExample) | ||
| RU2017141536A (ru) | Замещенные производные индол-5-ола и их терапевтические применения |